A potent oral multi-kinase inhibitor becoming studied in multiple tumor types.

The clinical need for these studies isn’t known and warrant additional investigation in a wide spectrum of tumors.. Bayer announces new data in novel anti-cancer compound Today announced outcomes from Phase We and II trials of BAY 73-4506 Bayer, a potent oral multi-kinase inhibitor becoming studied in multiple tumor types. These data were provided at the 45th Annual Achieving of the American Culture of Clinical Oncology . Bayer is focused on discovering brand-new cancer-fighting therapies, stated Kemal Malik, MD, Chief Medical Mind and Officer of Global Advancement at Bayer HealthCare. We are motivated by these Stage I and II data becoming presented on BAY 73-4506. These data can help additional determine our next measures as we progress with a thorough Phase III clinical advancement program in a variety of tumor types because of this new drug candidate.It continues to be unclear whether either of those controversial proposals will become law with less than two weeks left in the legislative session. Talks on Medicaid between Senate and House leaders began today. The Department of Health bill appears to be in the most danger of dying, as Senate committees have not considered the issue. Simultaneously, Home and Senate leaders would have to reach contract on revamping Medicaid — – no small task when coping with a $19 billion program that provides health care to 2.7 million people’ .